↓ Skip to main content

Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [11C]erlotinib PET

Overview of attention for article published in EJNMMI Research, February 2015
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#23 of 215)
  • Good Attention Score compared to outputs of the same age (74th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

twitter
1 tweeter
patent
1 patent

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
22 Mendeley
Title
Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [11C]erlotinib PET
Published in
EJNMMI Research, February 2015
DOI 10.1186/s13550-014-0080-0
Pubmed ID
Authors

Galith Abourbeh, Batel Itamar, Olga Salnikov, Sergey Beltsov, Eyal Mishani

Abstract

Non-small cell lung carcinoma (NSCLC) represents approximately 80% of lung cancer cases, and over 60% of these tumors express the epidermal growth factor receptor (EGFR). Activating mutations in the tyrosine kinase (TK) domain of the EGFR are detected in 10% to 30% of NSCLC patients, and evidence of their presence is a prerequisite for initiation of first-line therapy with selective TK inhibitors (TKIs), such as gefitinib and erlotinib. To date, the selection of candidate patients for first-line treatment with EGFR TKIs requires an invasive tumor biopsy to affirm the mutational status of the receptor. This study was designed to evaluate whether positron emission tomography (PET) of NSCLC tumor-bearing mice using [(11)C]erlotinib could distinguish erlotinib-sensitive from erlotinib-insensitive or erlotinib-resistant tumors. Four human NSCLC cell lines were employed, expressing either of the following forms of the EGFR: (i) the wild-type receptor (QG56 cells), (ii) a mutant with an exon 19 in-frame deletion (HCC827 cells), (iii) a mutant with the exon 21 L858R point mutation (NCI-H3255 cells), and (iv) a double mutant harboring the L858R and T790M mutations (NCI-H1975 cells). Sensitivity of each cell line to the anti-proliferative effect of erlotinib was determined in vitro. In vivo PET imaging studies following i.v. injection of [(11)C]erlotinib were carried out in nude mice bearing subcutaneous (s.c.) xenografts of the four cell lines. Cells harboring activating mutations in the EGFR TK domain (HCC827 and NCI-H3255) were approximately 1,000- and 100-fold more sensitive to erlotinib treatment in vitro, respectively, compared to the other two cell lines. [(11)C]Erlotinib PET scans could differentiate erlotinib-sensitive tumors from insensitive (QG56) or resistant (NCI-H1975) tumors already at 12 min after injection. Nonetheless, the uptake in HCC827 tumors was significantly higher than that in NCI-H3255, possibly reflecting differences in ATP and erlotinib affinities between the EGFR mutants. [(11)C]Erlotinib imaging in mice differentiates erlotinib-sensitive NSCLC tumors from erlotinib-insensitive or erlotinib-resistant ones.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 22 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 36%
Researcher 5 23%
Student > Master 3 14%
Other 1 5%
Student > Bachelor 1 5%
Other 1 5%
Unknown 3 14%
Readers by discipline Count As %
Agricultural and Biological Sciences 5 23%
Medicine and Dentistry 4 18%
Pharmacology, Toxicology and Pharmaceutical Science 3 14%
Chemistry 3 14%
Biochemistry, Genetics and Molecular Biology 1 5%
Other 1 5%
Unknown 5 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 July 2017.
All research outputs
#2,811,465
of 11,489,354 outputs
Outputs from EJNMMI Research
#23
of 215 outputs
Outputs of similar age
#65,018
of 255,468 outputs
Outputs of similar age from EJNMMI Research
#2
of 17 outputs
Altmetric has tracked 11,489,354 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 215 research outputs from this source. They receive a mean Attention Score of 1.7. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 255,468 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.